TP53 and neoplasm: Studies using small molecule inhibitors of the p53-MDM2 interaction such as nutlin and RITA (Reactivation of p53 and induction of tumor cell apoptosis) have shown the potential for pharmacological activation of p53 by disrupting the p53-MDM2 interaction as a new and promising anticancer strategy [4]–[8].